Neurodegenerative diseases (NDDs) involve years of gradual preclinical progression. It is widely anticipated that in order to be effective, treatments should target early stages of disease, but we lack conceptual frameworks to identify and treat early manifestations relevant to disease progression. Here we discuss evidence that a focus on physiological features of neuronal subpopulations most vulnerable to NDDs, and how those features are affected in disease, points to signaling pathways controlling excitation in selectively vulnerable neurons, and to mechanisms regulating calcium and energy homeostasis. These hypotheses could be tested in neuronal stress tests involving animal models or patient-derived iPS cells.
Introduction
Neurodegenerative diseases (NDDs) involve protracted preclinical phases that can last decades, and can include gradual buildup of pathology selectively in those neurons that will degenerate during end-stage disease (e.g., Saxena and Caroni, 2011) . Subsequent clinically detectable phases again last several years. They involve relentless progression of neuronal pathology, dysfunction, and degeneration leading to death. Although genes whose mutations can cause a particular NDD are often expressed ubiquitously throughout life, each of these diseases preferentially affects comparable and defined subpopulations of neurons (selective neuronal vulnerability), leading to the typical age-related clinical profile of each NDD. For some NDDs (e.g., frontotemporal dementia and amyotrophic lateral sclerosis [ALS] ), the same mutations can cause distinct NDDs in different individuals, or even combinations of NDDs in the same individual, suggesting that although the systems affected by particular mutations or insults can differ individually, the spectrum of affected neurons is characteristic of each NDD (Cooper-Knock et al., 2014; Deng et al., 2014) .
This review will discuss and compare findings in Parkinson's disease (PD), spinal cerebellar ataxia (SCA), ALS, Huntington's disease (HD), and Alzheimer's disease (AD). The physiological features of the neurons selectively affected in these NDDs do not exhibit obvious similarities, and the basis for their selective vulnerabilities has remained poorly understood. Little is understood about the factors that influence preclinical progression in the neurons vulnerable to disease. While advancing age clearly makes a key contribution (Jagust, 2013) , external factors such as damage to vasculature, inflammatory processes, and injuries have been convincingly implicated (Zlokovic, 2005; Zacchigna et al., 2008; Bjö rkqvist et al., 2009; Obermeier et al., 2013) . Notably, increasing disease-related pathology such as the accumulation of characteristic protein deposits or mild cognitive dysfunction does not invariantly progress to clinical disease. The factors that predict clinical disease progression are again poorly understood, but local deficits in energy metabolism and neuronal activity appear to predict progression (Palop et al., 2006) .
Despite major advances in dissecting genetic and cellular mechanisms underlying NDDs, fundamental questions have remained poorly understood. Two key unresolved issues are as follows:
(1) We lack a conceptual framework to investigate how individual pathogenic processes fit into a causal sequence of relevant progressive dysfunctions during preclinical and clinical phases of each disease. (2) We lack a conceptual framework to investigate the mechanistic basis of selective neuronal vulnerability in NDDs.
In this Perspective, we hypothesize that these two issues might be related, and that understanding factors underlying selective neuronal vulnerability might provide much needed guiding principles to unravel the logics of pathogenic process progression. Accordingly, we focus first on what might determine selective neuronal vulnerability in NDDs.
The gradual nature of preclinical and clinical disease progression processes at least in some NDDs selectively in vulnerable neurons (Saxena and Caroni, 2011) suggests that, at its core, disease progression might involve slow but relentless reduction of cell fitness in vulnerable neurons. This interpretation is supported by findings in animal models of ALS in which interventions that reduce pathology mainly slowed down progression of disease manifestations during treatment, suggesting that key disease-driving processes can continue to progress in the absence of prominent pathology, e.g., macroscopic protein deposits (Saxena et al., 2013) . Likewise, transient pathology-enhancing treatments had little influence on the time course of disease progression after treatment termination. These observations suggest that NDDs might involve slowly progressing fitness impairing processes in vulnerable neurons whose detection can be challenging, and which can be accompanied by a variety of secondary pathological processes (e.g., accumulation of protein aggregates, endoplasmic reticulum [ER] stress) that lead to important disease manifestations, but only have modest roles on disease progression. Accordingly, the study of causal relationships in neurodegenerative diseases is complicated by the fact that prominent disease manifestations might not have critical roles in disease progression.
Interestingly, although individual NDDs mostly affect different neurons and brain systems, subcellular targets of pathology such as mitochondria, autophagy, ER stress, and proteostasis have been reported in many of those diseases (Lin and Beal, 2006; Chan et al., 2009; Saxena and Caroni, 2011; Jagust, 2013; Hetz and Mollereau, 2014) . This suggests that individual NDDs might not be specifically linked to unique forms of subcellular pathology. Taken together, these considerations suggest that selective vulnerability might involve molecular pathways specific to a particular NDD, affecting key homeostatic processes in susceptible neuronal subpopulations. To explore this notion, we focus on what might be specific functional and homeostatic properties of neurons most affected in each particular NDD, and how those properties are affected during disease progression. Our analysis reveals common themes involving early silencing and alterations in the excitability of vulnerable neurons in NDDs. We suggest that, where it has been detected, enhanced excitability early in disease might be an adaptive response to boost neuroprotection in affected neurons (''acquired neuroprotection''; Bas-Orth and Bading, 2013; Saxena et al., 2013) . Whether enhanced excitability might also, or possibly even predominantly, be a maladaptive consequence of disease remains to be determined.
Parkinson's Disease PD, the second most common neurodegenerative disease, is predominantly, but not exclusively, a movement disorder. Early clinical manifestations typically include tremor at rest, rigidity, and difficulties in the initiation and control of movements, particularly gait. Additional symptoms include alterations in sensation, cognition, mood, and sleep. Substantia nigra pars compacta (SNc) dopaminergic (DA) are selectively vulnerable to PD. Typical PD pathology includes Lewy bodies with a-synuclein deposits. Causes of familial PD include mutations in a-Synuclein, parkin, LRRK2, PINK1, and DJ1.
SNc DA neurons selectively affected in PD exhibit unusual firing patterns in vivo, consisting of highly regulated phasic bursts superimposed onto autonomous tonic pacemaker activity (Schiemann et al., 2012) . At least for ventral tegmental area DA neurons, tonic firing regulation might modulate the saliency of DA signals released at bursts (Goto et al., 2007) . Tight negative regulation of SNc DA neuron burst firing depends on high-level expression of the small-conductance calcium-activated potassium channel SK3 (Stocker, 2004) and K-ATP channels in vulnerable nigral neurons (Wolfart et al., 2001; Wolfart and Roeper, 2002; Blythe et al., 2009; Schiemann et al., 2012) . The balance between tonic and phasic firing is influenced by SK3, and expression of human mutant SK3 in DA neurons leads to enhanced phasic firing by these neurons (Soden et al., 2013) . Pacemaking activity in adult SNc DA neurons is robust and likely depends on several ion channels, whereas pacemaking in juvenile SNc DA neurons depends on sodium and hyperpolarizationactivated cyclic nucleotide-gated channels (Chan et al., 2007; Guzman et al., 2009) . Furthermore, burst firing in SNc DA neurons depends on glutamatergic gating involving activation of NMDA receptors interacting with voltage-sensitive ion channels to overcome the inhibitory effects of the calcium-dependent conductance of SK3 (Deister et al., 2009 ). Possibly as a way to achieve fast calcium-dependent regulation of firing, SNc DA neurons exhibit low cytosolic calcium buffering capacity (Foehring et al., 2009) , which might put them at risk for calcium-dependent mitochondrial overload and pathology in neurodegeneration . In summary, vulnerable SNc DA neurons exhibit unusually intense, highly regulated firing properties that depend on fast oscillations in cytosolic calcium levels and on a high supply of energy sources (Figure 1) .
Several genetic and pharmacological animal models of PD target mitochondrial function, leading to elevated cytosolic calcium levels and reduced excitability of vulnerable SNc DA neurons Surmeier et al., 2010; Guzman et al., 2010; Surmeier et al., 2012; Masi et al., 2013; Hirsch et al., 2013) . The resulting silencing of vulnerable neurons involves both burst and pacemaking firing and precedes neuronal degeneration (Good et al., 2011; Michel et al., 2013) . Consistent with the existence of a causal relationship between hyperpolarization and degeneration, inhibition of slow potassium conductances or activation of sodium channels in vulnerable neurons is neuroprotective against genetic and toxic insults (Salthun-Lassalle et al., 2004; Chan et al., 2007; Alvarez-Fischer et al., 2013) . Greatly reduced firing before degeneration might account for the poor correlation between dysfunction and neuronal losses in PD. Notably, surviving DA neurons in PD exhibit increased NMDA receptor subunit NR1 and K-ATP subunit expression, and display up to 2-fold enhanced bursting rates. These studies suggest that enhanced in vivo burst firing might contribute to the selective vulnerability of DA SNc neurons, possibly reflecting an acquired vulnerability process (Liss et al., 2005; Schiemann et al., 2012; Subramaniam et al., 2014) . Taken together, several studies suggest that vulnerable SNc DA neurons exhibit reduced excitation due to reduced mitochondrial function and enhanced cytosolic calcium levels in PD, leading to silencing and subsequent degeneration of vulnerable neurons (Figure 1 ). In addition, enhanced excitability in PD might aggravate the vulnerability of DA SNc neurons.
Spinal Cerebellar Ataxia SCA is a group of up to 60 genetic disorders involving poor coordination of movement, including gait, hands, and speech. Cerebellar cortex GABAergic Purkinje cells (PCs) are selectively vulnerable in many forms of SCA. Several SCAs involve polyglutamine expansions; some forms are autosomal dominant, whereas others (e.g., Friedreich ataxia, ataxia telangiectasia) are autosomal recessive.
PCs particularly affected in SCA exhibit unusually intense and complex firing properties, consisting of cycles alternating between autonomous tonic activity, bursting activity, and silent periods (Figure 1 ). This striking complexity of PC firing is made possible by the expression of an array of calcium channels and calcium-activated potassium channels (Swensen and Bean, 2003; Foehring et al., 2009; Carter and Bean, 2011; Hosy et al., 2011; Forrest et al., 2012; Forrest, 2013) . Most important among them are P/Q-type voltage-gated calcium channels (sustain spontaneous bursting and dendritic calcium spiking), and T-type voltage-gated calcium channels, small-conductance (SK) and large-conductance (BK) calcium-dependent potassium channels. SK channels set the intrinsic firing frequency of PC (Stocker, 2004) , whereas BK channels regulate action potential shape. Notably, the extremely large dendrites have a prominent role in regulating neuronal excitability in PCs, where a dendritic calcium spike terminates each burst (Womack and Khodakhah, 2004) . The high reliance on calcium transients for regulating excitability might be reflected in high expression levels of the cytosolic calcium buffers parvalbumin and Calbindin-D28 in PC.
In ataxia models, PCs exhibit reduced spontaneous firing long before the onset of clinical symptoms and degeneration (Shakkottai et al., 2011) . Indeed, enhanced excitability in the targets of PCs (deep cerebellar nuclei neurons), an anticipated consequence of insufficient PC-mediated inhibition, was sufficient to cause cerebellar ataxia in the absence of PC degeneration (Shakkottai et al., 2004) . PC silencing in disease involves reduced parallel fiber input strength through a postsynaptic mechanism, and reduced intrinsic excitability, e.g., through increased voltage-dependent potassium currents (Hourez et al., 2011) . In SCA13, potassium channel mutations were sufficient to alter firing patterns and reduce excitatory input to PCs (Irie et al., 2014) , whereas in SCA1, delayed action potential generation was reduced by 4-aminopyridine, suggesting that it might be mediated by A-like potassium conductances (Inoue et al., 2001 ). Levels of the calcium buffering proteins parvalbumin and calbindin-D28 were reduced early in SCA2 (Hansen et al., 2013) , and treatments that alleviate ataxic symptoms and decrease PC pathology increased PC calbindin-D28 levels (Vig et al., 2012) . Furthermore, suppressing calbindin-D28 expression was sufficient to exacerbate disease in a mouse model of SCA1 (Vig et al., 2012) . Notably, restoration of normal firing properties or increasing PC excitability prevented PC degeneration (Hourez et al., 2011) . Taken together, these observations suggest that PCs selectively vulnerable to SCA exhibit unusually complex and highly regulated firing properties, including high-frequency basal firing, complex bursts, and firing suppression, which are all critically involved in how PCs regulate sensory-motor integration in behavior, and which involve somatic and dendritic regulation through calcium fluxes ( Figure 1 ). PC calcium buffers and firing are lost early in disease, leading to ataxia symptoms and to late degeneration of PCs ( Figure 1 ).
Amyotrophic Lateral Sclerosis ALS (a.k.a. Lou Gehrig's disease), the most common form of motoneuron disease, leads to progressive paralysis of skeletal muscles. The disease can start at limbs or at facial muscles. Top row: SNc DA neurons (left) highly vulnerable to PD exhibit alternating pacemaker and bursting activity (center). NMDA receptor activation and inhibition of K-ATP channels are important to drive bursting activity (red), and calcium-dependent channels (e.g., SK) are important for pacemaking activity (blue). PD (right) involves mitochondrial pathology (yellow; reduced calcium uptake indicated by smaller blue arrow), excess cytosolic calcium (blue dots) and excess K channel opening as a result of decreased ATP availability and excess cytosolic calcium, leading to reduced excitation (broad blue bar). Middle row: PCs (left) particularly vulnerable to SCAs exhibit alternations of pacemaking activity, bursting activity, and no activity (center). PCs exhibit high levels of cytosolic calcium buffers (ovals), which are greatly reduced in disease (right, yellow). Bursting is regulated in part by dendritic calcium fluxes, whereas suppression of firing involves K conductances. SCA (right) involves elevated cytosolic calcium levels, and (at least in SCA1) elevated SK activity, leading to greatly reduced PC firing. Lower row: spinal MNs (left) particularly vulnerable in ALS exhibit high-threshold burst firing activity (center). Burst firing is suppressed by K conductances (blue), particularly SK channels. ALS (right) involves ER and mitochondrial pathology (yellow) and elevated cytosolic calcium levels, leading to suppression of MN firing.
MNs vulnerable to ALS drive all skeletal muscle activity, and thus the behavioral output of the nervous system. To achieve this, their firing properties are under tight and complex regulatory control (Figures 1 and 2 ). Individual spinal MNs receive tens of thousands of synaptic inputs from a high number of distinct neuronal sources (Kanning et al., 2010; Deardorff et al., 2013) . Those inputs are not sufficient to drive MN spiking, which is gated by neuromodulators. Among alpha-MNs, fast-fatigable MNs are particularly vulnerable to ALS. They exhibit highest thresholds for excitation, are recruited infrequently to produce brief and intense force, fire in bursts, and might express higher levels of calcium-activated SK channels (Saxena and Caroni, 2011; Mü ller et al., 2014) . In contrast, least vulnerable slow MNs exhibit low recruitment thresholds, are recruited frequently during wakefulness, and exhibit tonic firing. Reflecting fast regulation through intracellular calcium transients, vulnerable alphaMNs express low levels of cytosolic calcium buffering proteins and are subjected to large and fast calcium fluxes across intracellular organelles such as mitochondria and smooth ER (Kanning et al., 2010) . Finally, alpha-MNs exhibit particularly large dendritic trees, and the most vulnerable fast-fatigable MNs innervate particularly large numbers of muscle fibers (Saxena and Caroni, 2011) . Taken together, the most vulnerable MNs exhibit highest recruitment thresholds, firing rarely, and in bursts. Large intracellular calcium fluxes and large numbers of neuromuscular junctions lead to particularly high energetic demands for function in these neurons.
Fast-fatigable MNs exhibit early pathology and loss of function followed by peripheral denervation in mutant-SOD1 mouse models of ALS (Saxena and Caroni, 2011) . Early loss of function by fast-fatigable MNs was also reported in other models of motoneuron disease and in human patients (Kanning et al., 2010) . In mutant SOD1 mice, MNs exhibit early hypo-excitability and a fraction of them already fails to produce sustained firing early in disease (Figure 1) (Saxena et al., 2013; Delestré e et al., 2014) . Pathology is closely correlated with increases in cytosolic calcium and downregulation of the ER calcium regulating protein calreticulin. Furthermore, in mutant C9Orf72 ALS motoneurons derived from patient iPS cells, repetitive firing induced by current injections was reduced (Sareen et al., 2013) . A recent study provided evidence that enhancing MN excitability in ALS mice delays pathology and extends survival, whereas reducing MN excitability is sufficient to produce pathology and early denervation in more resistant slow MNs (Saxena et al., 2013) . Notably, similar early failure to produce firing activity was reported for MNs in mouse and Drosophila models of spinal muscular atrophy (SMA), a rapidly progressing early onset motoneuron disease (Mentis et al., 2011) . In the SMA model failures in MN excitation involved defects in proprioceptive Ia synaptic excitation of MNs, and MN degeneration could be rescued by either direct activation of MNs or by correcting the mutation in primary afferent proprioceptive neurons (Figure 2) Imlach et al., 2012) . These findings of how MNs are affected in SMA are reminiscent of non-cell-autonomous mechanisms of disease in HD, where loss of cortical input activity leads to inactivation and degeneration of vulnerable medium spiny neurons (see below).
Huntington's Disease HD is a genetic disorder affecting muscle coordination and cognition. Early clinical manifestations typically include a lack of coordination and of gait control, as well as jerky movements. Cognitive disabilities are detected early in disease, and progress to dementia; sleep disturbances are also common. Striatal medium spiny GABAergic neurons (MSNs), particularly those of the indirect pathway regulated through D2-type DA receptors, are selectively vulnerable to HD. Typical HD pathology involves inclusion bodies enriched in Huntingtin. HD is caused by CAG expansions in the Huntingtin gene.
MSNs most vulnerable in HD exhibit highly controlled and sparse spiking activities modulated by cortico-striatal up and down states (Berke et al., 2004; Mahon et al., 2006) . These neurons receive thousands of weak cortical inputs, and exhibit high-threshold firing properties gated by DA and NMDA receptor activation (Shen et al., 2007; Pomata et al., 2008) . The dependence on a large numbers of excitatory inputs for activation might render these neurons particularly vulnerable to loss of cortical excitation.
Like in other NDDs, vulnerable MSNs receive less excitatory drive long before they degenerate in HD (Cepeda et al., 2003; Raymond et al., 2011) . Furthermore, correlated burst firing between MSN neurons is reduced in HD mouse models (Miller et al., 2008) . MSN neurons of the less affected direct pathway (D1-type DA receptor) exhibit early hypercitability, which might compensate for a reduced synaptic drive from cortex . Cortical neurons degenerate in HD, and their axons projecting to subcortical targets including striatum are compromised early in disease (Cepeda et al., 2003; Spampanato et al., 2008) . Notably, although cortical neuron degeneration occurs after that of MSNs, reduced functionality of cortical neurons is critical to MSN degeneration (Gu et al., 2005; Xie et al., 2010) . Thus, a recent targeted rescue study in a mouse model of HD provided evidence that it is the combination of mutant Huntingtin in cortical neurons and in MSNs that accounts for MSN degeneration and striatal dysfunction . HD might therefore initially involve deficits in neurons synapsing onto MSNs (Cummings et al., 2009; Thomas et al., 2011 ), but the degeneration is then most pronounced in MSNs (Cowan et al., 2008) . In other words, mutant Huntingtin might not be sufficient to cause loss of excitation and degeneration of MSNs in HD, but combined with loss of critical excitatory inputs by cortical neurons, it then causes degeneration in MSNs (Figure 2 ). In MSNs, mutant Huntingtin appears to impair mitochondrial function (Damiano et al., 2013) , which might predispose these neurons to vulnerability due to absence of excitation.
Alzheimer's Disease AD is the most common neurodegenerative disease, and the most common cause of late-onset dementia. Early clinical manifestations typically include short-term memory losses. As AD advances, confusion, mood swings, apathy, and long-term memory losses become more prevalent. Typical AD pathology includes extracellular amyloid plaques enriched in beta amyloid (Ab), and neurofibrillary tangles enriched in hyper-phosphorylated Tau. Causes of familial AD include mutations in APP and Presenilins 1 and 2.
Unlike other major NDDs, AD does not seem to preferentially target a particular subpopulation of neurons. Instead, interneurons and principal neurons in a small number of cortical structures are affected early in disease, leading to characteristic memory and cognitive deficits. While AD is generally associated with reduced excitatory synaptic activity, hyperactivity of some neurons is frequent very early in AD mice. This hyperactivity of subsets of principal neurons appears to involve direct local effects of soluble Ab, and reduced inhibition through parvalbumin-positive interneurons (Busche et al., 2012; Verret et al., 2012) . In mouse models of AD, early disease stages involve comparable numbers of silent and hyperactive neurons, particularly in the vicinity of amyloid plaques (Busche et al., 2008; Grienberger et al., 2012) . Recent human neuroimaging data suggest that resting-state functional connectivity strength is reduced in patients with AD (Buckner et al., 2009; Gleichmann and Mattson, 2010) . Interestingly, Ab deposition from interstitial fluid initially appears to be most pronounced near more functionally active networks, where it then reduces network activity (Bero et al., 2011 (Bero et al., , 2012 ; likewise, tau release from neurons is influenced by neuronal activity (Yamada et al., 2014) . Notably, IP3 receptor signaling is dysregulated in AD model mice, and Ryanodine receptor is upregulated in AD-derived tissue, in AD mice, and upon stress, leading to enhanced release of calcium into the cytosol and decreased excitability due to activation of SK channels (Stutzmann et al., 2004 (Stutzmann et al., , 2006 Liu et al., 2012; Demuro and Parker, 2013) . In sum, AD shares with other NDDs a loss of neuronal activation long before neuronal degeneration, and possibly also before loss of synapses (Gleichmann et al., 2012) . However, due to a relative lack of experimental data concerning neuronal subpopulations particularly vulnerable to AD, it is currently not possible to relate firing properties of susceptible neurons to their silencing and degeneration in AD.
Selective Neuronal Vulnerability to Loss of Excitation in Disease
A comparison of neurons particularly vulnerable to NDDs, focusing on their physiological properties under healthy conditions and in disease, reveals potentially interesting similarities (Figures 1 and 2) . Selectively vulnerable neurons exhibit narrowly regulated firing properties, including powerful mechanisms to prevent firing or constrain its patterns in response to specific signals. To implement tight regulatory demands on firing, vulnerable neurons tend to exhibit high reliance on fast cytosolic calcium signaling and/or high levels of intracellular calcium trafficking Hirsch et al., 2013) . A comparison among selectively vulnerable neurons suggests that they might achieve tight regulation of firing through distinct signaling strategies involving calcium regulation. Thus, MNs and SNc DA neurons exhibit low levels of intracellular calcium buffers, and high reliance on mitochondria for rapid termination of calcium signals, whereas PCs exhibit high reliance on calcium release from the ER for signaling, and exceptionally high contents of cytosolic calcium buffers for signal termination. We suggest that while calcium codes might differ in the different types of vulnerable neurons, what might render them particularly susceptible to disease is their high dependence on proper cellular homeostasis for both excitation and acquired neuroprotection through calcium signaling pathways. Consistent with this notion, selectively vulnerable neurons tend to lose firing activity before detection of clinical manifestations. Furthermore, increased neuronal excitability early in disease might be a compensatory mechanism to provide critical neuroprotection to affected neurons. A selective loss of excitation can have an important role in aggravating disease progression both in vulnerable neurons and through consequences of neuronal dysfunction for network performance and behavior (Palop et al., 2006; Gleichmann and Mattson, 2010) . Furthermore, loss of excitation can be a cellautonomous process in neurons that will degenerate, or can be due to disease-related activity deficits in critical input neurons. In both cases, lack of excitation can promote disease-related degeneration in vulnerable neurons, suggesting that the combination of disease-related vulnerability and loss of excitation can have a major role in driving disease.
Although similarities among vulnerable neurons as highlighted above are suggestive, whether they reflect appropriate classifications and are indeed relevant to disease remains to be determined. Thus, in the absence of experimental evidence directly investigating causal relationships between selective neuronal vulnerability to particular NDDs and intrinsic neuronal mechanisms relating control of excitation to intracellular signaling, as well as between disease-related disruption of excitation in vulnerable neurons and disease progression, apparent aspects of commonality as emphasized above might be anecdotal. Furthermore, the role of enhanced excitability in NDDs has been difficult to assess, and alternative models emphasize excess excitation as a major factor in disease progression (e.g., Mattson, 2003; Chan et al., 2009) . Nevertheless, two questions warrant further consideration at this point: (1) what diseaserelated mechanisms might render selectively vulnerable neurons particularly prone to loss of excitation, and (2) how loss of excitation might aggravate disease progression in vulnerable neurons. It should be noted that in the absence of a disease context, e.g., expression of a disease-causing mutant, suppression of excitation or enhancement of cell stress were not sufficient to produce pathology and degeneration in vulnerable neurons (Saxena et al., 2013) . In good agreement with the framework described above, this suggests that early disease-related processes specifically compromise subpopulations of vulnerable neurons in disease, rendering these neurons particularly sensitive to loss of excitation, and dependent on excitability for neuroprotection.
What cellular pathogenic mechanisms associated with NDDs might lead to disruption and loss of excitation in vulnerable neurons? Direct reductions in the strength of excitatory inputs, e.g., through alterations in glutamate receptor regulation, or in individual pathways supporting neuronal excitability might not persistently lead to loss of excitation because of homeostatic mechanisms aimed at adjusting the strength of neuronal inputs within values consistent with network function. In contrast, disease processes targeting basic cellular mechanisms coupled to neuronal excitability should have major consequences on neuronal excitation. Among them, persistent enhancements in neuronal cytosolic calcium levels and/or deficits in energy production can suppress excitability through calcium-dependent potassium conductances and have been frequently associated with NDDs and with disease-related pathological processes Hirsch et al., 2013) . Calcium homeostasis interfaces with proteostasis mechanisms at ER and Golgi membranes, and with most major intracellular signaling pathways (Lin and Beal, 2006; Bading, 2013; Hetz and Mollereau, 2014) . Accordingly, its disruption can have powerful negative consequences on neuronal homeostasis mechanisms. Candidate disease-related mechanisms that might target calcium homeostasis include deficits in neuronal energy production, and deficits in intracellular organelle systems that influence ion fluxes and couple these processes to excitation. Consistent with this notion, many pathogenic processes in NDDs appear to target mitochondrial function and/or calcium metabolism, either directly or indirectly (e.g., Lin and Beal, 2006; Chan et al., 2009; Hirsch et al., 2013) .
Several mechanisms could link loss of excitation to severe disease progression in vulnerable, partially compromised neurons. At the synaptic level, reductions in the ratio of synaptic versus extrasynaptic NMDA receptor activation have been shown to impair neuroprotection and enhance processes that compromise neuronal homeostasis (Bading, 2013) . Thus, synaptic NMDA receptor activation and burst firing enhance neuronal functions and neuroprotection through a range of key mechanisms, including nuclear calcium signaling and activation of CREB-mediated gene expression, transport of the transcriptional co-activator CRTC1 from synapse to nucleus, and activation of BDNF gene expression (Ghosh et al., 1994; Hardingham et al., 2001; Zhang et al., 2007; Ch'ng et al., 2012; Bading, 2013; Karpova et al., 2013) . Furthermore, several CREB target genes have potent neuroprotective roles (Hardingham and Bading, 2010) . In contrast, extrasynaptic NMDA receptor signaling, which is frequently enhanced in NDDs (Milnerwood et al., 2010) , interferes with several neuroprotective pathways and counteracts CREB activation (Hardingham et al., 2002; Xu et al., 2009; Wang et al., 2013; Karpova et al., 2013; Parsons and Raymond, 2014) . Furthermore, patterns of neuronal firing have major consequences on neuronal gene expression and function (Xiang et al., 2007; Ma et al., 2011) . Thus, tonic and bursting firing patterns recruit distinct voltage-dependent calcium channels and intracellular calcium-transporting organelles, differentially modulating CREB-dependent gene expression (Wheeler et al., 2012) . Likewise, phasic and tonic firing patterns can recruit different levels of key transcription factors such as NFAT family members (Herná ndez-Ochoa et al., 2007) . Finally, reductions in neuronal firing can cause calcium depletion from ER stores, leading e.g., to ubiquitin-dependent degradation of Sp4, a transcription factor involved in synaptic plasticity (Lalonde et al., 2014) . On the other hand, excess excitation can have powerful toxic effects on neurons, e.g., in epilepsy and stroke (Lai et al., 2014) . The extent to which excess excitation has a major role in NDDs has remained a complex issue (Yano et al., 1998; Mattson, 2003; Soriano et al., 2006; Sasaki et al., 2010) , but one mechanism might involve a relative excess in extrasynaptic NMDA receptor activation, through elevated extrasynaptic receptor levels, elevated extrasynaptic glutamate levels, and/or reduced synaptic NMDA receptor activation (Okamoto et al., 2009; Milnerwood et al., 2010; Parsons and Raymond, 2014) .
Models
The observations outlined above can be combined into simplified general models of how disease-related mechanisms affecting selectively vulnerable neurons might influence disease progression in NDDs (Figure 3 ). The models are based on the key role of excitation, e.g., through synaptic NMDA receptors, to promote neuroprotection, on observations that disease-causing genes can affect cellular processes (e.g., mitochondrial homeostasis) at the intersection between pathways controlling excitability and supporting neuronal fitness, and on the narrow reliance by vulnerable neurons on these two types of factors. Although many of the premises require experimental validation (see next section for example), these models might be useful to formulate testable hypotheses about mechanisms of disease.
Studies on animal models of NDDs suggest that a first level of specificity should relate disease-related mechanisms, e.g., the molecular pathways affected by particular disease-causing mutations, to a subset of the neurons that can be affected in NDDs (Figure 3 ). This specificity might be defined by a match between molecular mechanisms affected by disease-related proteins and a particular reliance of targeted neurons on those mechanisms (e.g., mitochondria in PD). A second requirement of these models (second hit) is that, in vulnerable neurons, the consequences of disease-related protein interference should negatively impact critical mechanisms affecting excitation, e.g., through calcium homeostasis (Figure 3 ; as discussed in the previous sections of this Perspective, this might apply generally to neurons selectively vulnerable in NDDs). Together, these two specificity requirements should focus disease-related processes to a specific (vulnerable) subset of those neurons in which alterations in specific aspects of cellular (e.g., calcium and/or energy) homeostasis readily lead to deficits in excitation. Different NDDs would involve distinct subsets of neurons, but some of the molecular mechanisms could be at the origin of several distinct NDDs (Figure 3 ). The reduction in excitation might lead to compensatory enhanced excitability, which in this view would be adaptive, but could become maladaptive (possibly leading to further acquired vulnerability, e.g., in PD). A third critical step in disease progression would involve progressive reduction of excitation in vulnerable neurons, e.g., as a function of age or increasing cell stress. This reduction might involve intrinsic mechanisms, and/or disease-related losses in critical excitatory inputs to vulnerable neurons (Figure 3) . Loss of excitation beyond a critical level might initiate more severe disease progression, including degenerative processes in targeted neurons, implication of local environment cells such as microglia, astrocytes, and vasculature epithelial cells through stress responses and exosome-mediated spillover of disease-related toxic products, and functional losses leading to clinically detectable symptoms of disease (Zacchigna et al., 2008; Ilieva et al., 2009; Bjö rkqvist et al., 2009; Hetz and Mollereau, 2014) .
Conclusions and Implications
Here we suggest that factors leading to NDDs (e.g., gain-offunction mutations, or combinations of genetic background and adverse factors such damage to local vasculature) might compromise key cellular mechanisms that influence neuronal excitability, and that the neurons particularly vulnerable to NDDs might exhibit excitation-regulation features that put them at higher risk for excitability loss and homeostasis imbalance. Accordingly, intracellular pathways more likely to confer risk factors for vulnerability to NDDs might involve cellular hubs in which regulation of excitability and neuronal homeostasis overlap in vulnerable neurons. Slow but relentless progression might involve a gradual increase in intrinsic and environmentderived cellular stressors influenced by age in affected neurons. In addition to diffusion and intracellular transport of toxic protein species, spread of disease among interconnected neurons might involve impairment of presynaptic excitation. Thus, initial impairments in more vulnerable neuronal subpopulations in the network might impose additional load on interconnected subpopulations, enhancing their vulnerability in a disease context. The model predicts that factors directly relevant to disease progression should further decrease the dynamic range of neuronal excitability regulation and homeostatic resilience in vulnerable neurons. These predictions could be tested in neuronal stress tests, in which physiological input-output relationships of vulnerable neurons would be measured across a range of increasingly challenging conditions. Likewise, candidate interventions that might have an impact on disease progression should restore the physiological responses of vulnerable neurons in stress tests.
Regardless of the extent to which our analysis captures essential features of factors involved in NDD progression, we suggest that much-needed advances in elucidating disease-driving mechanisms in NDDs will depend on discovering disease-relevant cellular targets of mutant proteins that cause particular NDDs. So far, this has been challenging because individual disease-relevant mutants have turned out to affect a confusing variety of pathways in neurons. A focus on pathways that influence excitability in vulnerable neurons might help to zoom in on potentially relevant targets. This research could be carried out in animal models based on human mutations that exhibit slowly progressing neurodegeneration and mimic the corresponding human disease. In addition, a potentially promising option involves corresponding studies in vulnerable neurons differentiated from patient-derived iPS cells. However, whether those cultured iPS-derived neurons will reproduce relevant features of the disease remains to be determined.
In conclusion, our comparison of neurons particularly affected in NDDs suggests the existence of recurring themes involving complex and often intense firing patterns, tight control of A particular disease-relevant mutant protein and/ or a local insult affect neurons to varying degrees (yellow shades), defining subpopulations of sensitive neurons. Among sensitive neurons, those in which excitation is highly sensitive to alterations in the pathways affected by disease-relevant mutations or insults (e.g., calcium and/or energy homeostasis) are selectively vulnerable to disease (dark yellow [NDD-1], or pink [NDD-2]). Disease progression then involves age-and stressdependent loss of excitation, alterations in the local microenvironment (e.g., vasculature, immune cells, glia, interconnected neurons), leading to clinical manifestations of disease. The schematic further indicates that the same disease-related agents can cause distinct NDDs (NDD-1 and/or NDD-2) by initially (or preferentially) affecting distinct subpopulations of selectively vulnerable neurons in distinct individuals.
excitation, and dynamic regulation of excitability relying on high cytosolic calcium fluxes. We suggest that in a NDD setting these factors put vulnerable neurons at risk for loss of excitation through elevated cytosolic calcium levels, which in turn promotes progression and spread of degeneration. Should its relevance be validated, the framework discussed in this review should serve to focus mechanistic studies of disease initiation and progression on relevant core features of the disease process. Likewise, a focus on supporting excitability pathways in vulnerable neurons might lead to novel strategies to alleviate symptoms and slow down progression in NDDs. 
